{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:18:10Z","timestamp":1788013090512,"version":"build-2784847793"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T00:00:00Z","timestamp":1781395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T00:00:00Z","timestamp":1781395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shenzhen Science and Technology Program","award":["JCYJ20230807110405012"],"award-info":[{"award-number":["JCYJ20230807110405012"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82400245"],"award-info":[{"award-number":["82400245"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s43441-026-00967-3","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T14:58:41Z","timestamp":1781449121000},"page":"1453-1458","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular Toxicity of Monoclonal Antibodies Approved for Multiple Myeloma: Evidence Based on FAERS Database"],"prefix":"10.1007","volume":"60","author":[{"given":"Ting","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,14]]},"reference":[{"key":"967_CR1","doi-asserted-by":"publisher","first-page":"102284","DOI":"10.1016\/j.ctrv.2021.102284","volume":"100","author":"P Rodriguez-Otero","year":"2021","unstructured":"Rodriguez-Otero P, Paiva B, San-Miguel JF. Roadmap to cure multiple myeloma. Cancer Treat Rev. 2021;100:102284.","journal-title":"Cancer Treat Rev"},{"issue":"24","key":"967_CR2","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232\u201344.","journal-title":"N Engl J Med"},{"issue":"19","key":"967_CR3","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","volume":"379","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379(19):1811\u201322.","journal-title":"N Engl J Med"},{"issue":"17","key":"967_CR4","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","volume":"391","author":"T Facon","year":"2024","unstructured":"Facon T, Dimopoulos MA, Leleu XP, et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391(17):1597\u2013609.","journal-title":"N Engl J Med"},{"issue":"5","key":"967_CR5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2405090","volume":"391","author":"V Hungria","year":"2024","unstructured":"Hungria V, Robak P, Hus M, et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391(5):393\u2013407.","journal-title":"N Engl J Med"},{"issue":"9","key":"967_CR6","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259\u201367.","journal-title":"Nat Med"},{"issue":"6","key":"967_CR7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495\u2013505.","journal-title":"N Engl J Med"},{"issue":"8","key":"967_CR8","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936\u201345.","journal-title":"Blood"},{"issue":"6","key":"967_CR9","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40262-023-01240-8","volume":"62","author":"K Kim","year":"2023","unstructured":"Kim K, Phelps MA. Clinical pharmacokinetics and pharmacodynamics of daratumumab. Clin Pharmacokinet. 2023;62(6):789\u2013806.","journal-title":"Clin Pharmacokinet"},{"key":"967_CR10","doi-asserted-by":"publisher","first-page":"684561","DOI":"10.3389\/fonc.2021.684561","volume":"11","author":"A Romano","year":"2021","unstructured":"Romano A, Storti P, Marchica V, et al. Mechanisms of action of the new antibodies in use in multiple myeloma. Front Oncol. 2021;11:684561.","journal-title":"Front Oncol"},{"issue":"9","key":"967_CR11","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1182\/blood.2020008209","volume":"137","author":"M Dimopoulos","year":"2021","unstructured":"Dimopoulos M, Bringhen S, Anttila P, et al. Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed\/refractory multiple myeloma. Blood. 2021;137(9):1154\u201365.","journal-title":"Blood"},{"issue":"10245","key":"967_CR12","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","volume":"396","author":"M Dimopoulos","year":"2020","unstructured":"Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396(10245):186\u201397.","journal-title":"Lancet"},{"issue":"2","key":"967_CR13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nbt.2113","volume":"30","author":"R Bohm","year":"2012","unstructured":"Bohm R, Hocker J, Cascorbi I, et al. OpenVigil\u2013free eyeballs on AERS pharmacovigilance data. Nat Biotechnol. 2012;30(2):137\u20138.","journal-title":"Nat Biotechnol"},{"key":"967_CR14","doi-asserted-by":"publisher","first-page":"735466","DOI":"10.3389\/fcvm.2021.735466","volume":"8","author":"Y Zhai","year":"2021","unstructured":"Zhai Y, Ye X, Hu F, et al. Cardiovascular toxicity of carfilzomib: the real-world evidence based on the adverse event reporting system database of the FDA, the United States. Front Cardiovasc Med. 2021;8:735466.","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"967_CR15","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1517\/14740338.2016.1167184","volume":"15","author":"PS Ang","year":"2016","unstructured":"Ang PS, Chen Z, Chan CL, et al. Data mining spontaneous adverse drug event reports for safety signals in Singapore - a comparison of three different disproportionality measures. Expert Opin Drug Saf. 2016;15(5):583\u201390.","journal-title":"Expert Opin Drug Saf"},{"issue":"8","key":"967_CR16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13(8):519\u201323.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"967_CR17","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2165\/00002018-200023060-00004","volume":"23","author":"M Lindquist","year":"2000","unstructured":"Lindquist M, Stahl M, Bate A, et al. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf. 2000;23(6):533\u201342.","journal-title":"Drug Saf"},{"issue":"3","key":"967_CR18","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/ijc.30745","volume":"141","author":"MM Epstein","year":"2017","unstructured":"Epstein MM, Divine G, Chao CR, et al. Statin use and risk of multiple myeloma: an analysis from the cancer research network. Int J Cancer. 2017;141(3):480\u20137.","journal-title":"Int J Cancer"},{"issue":"1","key":"967_CR19","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","volume":"34","author":"T Facon","year":"2020","unstructured":"Facon T, Dimopoulos MA, Meuleman N, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020;34(1):224\u201333.","journal-title":"Leukemia"},{"key":"967_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2147\/ITT.S306103","volume":"10","author":"HN Abramson","year":"2021","unstructured":"Abramson HN. Immunotherapy of multiple myeloma: promise and challenges. Immunotargets Ther. 2021;10:343\u201371.","journal-title":"Immunotargets Ther"},{"issue":"6","key":"967_CR21","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1158\/2643-3230.BCD-23-0176","volume":"4","author":"R Firestone","year":"2023","unstructured":"Firestone R, Lesokhin AM, Usmani SZ. An embarrassment of riches: three FDA-approved bispecific antibodies for relapsed refractory multiple myeloma. Blood Cancer Discov. 2023;4(6):433\u20136.","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"967_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s44228-022-00017-3","volume":"4","author":"A Ibrahim","year":"2022","unstructured":"Ibrahim A, Chamseddine N, El-Cheikh J, et al. Management of multiple myeloma in the middle east: unmet needs, challenges and perspective. Clin Hematol Int. 2022;4(4):127\u201332.","journal-title":"Clin Hematol Int"},{"issue":"22","key":"967_CR23","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1136\/heartjnl-2020-318748","volume":"107","author":"M Fontes Oliveira","year":"2021","unstructured":"Fontes Oliveira M, Naaktgeboren WR, Hua A, et al. Optimising cardiovascular care of patients with multiple myeloma. Heart. 2021;107(22):1774\u201382.","journal-title":"Heart"},{"issue":"1","key":"967_CR24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-023-00849-z","volume":"13","author":"J El-Cheikh","year":"2023","unstructured":"El-Cheikh J, Moukalled N, Malard F, et al. Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies. Blood Cancer J. 2023;13(1):83.","journal-title":"Blood Cancer J"},{"issue":"20","key":"967_CR25","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.3390\/cancers13205057","volume":"13","author":"E Terpos","year":"2021","unstructured":"Terpos E, Stamatelopoulos K, Makris N, et al. Daratumumab may attenuate cardiac dysfunction related to carfilzomib in patients with relapsed\/refractory multiple myeloma: a prospective study. Cancers (Basel). 2021;13(20):5057.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"967_CR26","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/bjh.14787","volume":"178","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Lonial S, White D, et al. Elotuzumab plus lenalidomide\/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017;178(6):896\u2013905.","journal-title":"Br J Haematol"},{"issue":"10292","key":"967_CR27","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","volume":"397","author":"P Moreau","year":"2021","unstructured":"Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397(10292):2361\u201371.","journal-title":"Lancet"},{"key":"967_CR28","doi-asserted-by":"publisher","first-page":"1130636","DOI":"10.3389\/fpsyt.2023.1130636","volume":"14","author":"G Cicala","year":"2023","unstructured":"Cicala G, de Filippis R, Barbieri MA, et al. Tolerability profile of paliperidone palmitate formulations: a pharmacovigilance analysis of the EUDRAVigilance database. Front Psychiat. 2023;14:1130636.","journal-title":"Front Psychiat"},{"key":"967_CR29","doi-asserted-by":"publisher","first-page":"964399","DOI":"10.3389\/fphar.2022.964399","volume":"13","author":"K Pozsgai","year":"2022","unstructured":"Pozsgai K, Szucs G, Konig-Peter A, et al. Analysis of pharmacovigilance databases for spontaneous reports of adverse drug reactions related to substandard and falsified medical products: A descriptive study. Front Pharmacol. 2022;13:964399.","journal-title":"Front Pharmacol"},{"issue":"6","key":"967_CR30","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"JL Montastruc","year":"2011","unstructured":"Montastruc JL, Sommet A, Bagheri H, et al. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72(6):905\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"967_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-00967-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-00967-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-00967-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:47:17Z","timestamp":1788011237000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-026-00967-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,14]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["967"],"URL":"https:\/\/doi.org\/10.1007\/s43441-026-00967-3","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,14]]},"assertion":[{"value":"17 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}